跳至主要内容
临床试验/NCT00851578
NCT00851578已完成不适用

ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology

Boston Scientific Corporation4 个研究点 分布在 2 个国家目标入组 150 人开始时间: 2009年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
4
主要终点
Feasibility study to characterize the performance of the WATCHMAN LAA Closure device in atrial fibrillation patients contracindicated to warfarin treatment

研究概览

简要总结

The purpose of the study is to characterize the performance of the WATCHMAN LAA Closure Device in atrial fibrillation patients for which long term warfarin therapy is contraindicated.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 years of age or older
  • •paroxysma, persistent, or permanent non-vlavular atrial fibrillation
  • •contraindicated to warfarin
  • •eligible for clopidogrel, ticlopdine, heparin, or aspirin
  • •CHADS score 1 or greater

排除标准

  • •NYHA Class IV
  • •LAA obliteration
  • •Heart transplant
  • •LVEF less than 30%
  • •greater than 50% carotid stenosis

研究组 & 干预措施

WATCHMAN

Experimental

non-valvular atrial fibrillation patients contraindicated to warfarin

干预措施: WATCHMAN (Device)

结局指标

主要结局

Feasibility study to characterize the performance of the WATCHMAN LAA Closure device in atrial fibrillation patients contracindicated to warfarin treatment

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验